Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Cancer Prev Res (Phila). 2013 Dec;6(12):10.1158/1940-6207.CAPR-13-0079. doi: 10.1158/1940-6207.CAPR-13-0079

Figure 2. DMI Treatment Increased Tumor Growth but not Metastasis.

Figure 2

Mice were implanted with 10 mg DMI or placebo continuous release pellets 2 days before 4T1 inoculation. Tumor growth expressed as volume (A) or normalized (B) and as tumor weight (C). Lung metastasis (D) were measured 14 days post-4T1 injection. (E) Representative H&E-stained lung with metastatic lesion indicated by arrow. 4X objective lens; scale bar = 200 μm. (A–D) Results represent one of two experimental replications at each time point. For (H) and (I) results from two experimental repetitions were normalized relative to the respective placebo controls. Results are expressed as mean ± SEM, n=6–7 mice per group for day 7 and 12, n=9–10 per group day 14 post-4T1 injection. Statistical analyses: (A) main effect of DMI treatment, p = 0.047; treatment × time interaction, p <0.0001; main effect of time, p <0.0001; (B) main effect of DMI treatment, p = 0.0005; treatment × time interaction, p=0.0001, main effect of time, p<0.0001; (C) Tumor weight: main effect of DMI, p = 0.02; DMI × time interaction, p = 0.04, main effect of time, p <0.0001; (D) Lung metastasis: Student's t-test, p = 0.6; (F) VEGF: DMI treatment, p = 0.0006, no interaction or effect of time; (G) IL-6: main effect of DMI treatment, p=0.004, no DMI × time interaction, main effect of time, p = 0.0001; (H) tumor NMN: DMI × time interaction, p = 0.02). Asterisks indicate significant differences versus corresponding placebo control group by Holm-Sidak's multiple comparisons test (p<0.05).